bioAffinity Technologies Inc BIAF

US Biotechnology

$0.63 ▼ -2.64% ($-0.02)

🎈 Low Float 🗓️ Earnings Next Week

Open $0.64

Prev Close $0.64

Day Range $0.59 – $0.64

52W Range $0.56 – $13.50

Market Cap $3.94M

Beta -1.05

EPS (TTM) $-11.32

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2022-08-26
Shares Out.	7,780,000
Website	bioaffinitytech.com/ ↗
Phone	12106985334
Employees	57
Revenue	$1.4M
Gross Profit	$1.4M
Net Income	-$3.6M
Free Cash Flow	-$10.9M
Total Assets	$7.9M
Total Liabilities	$4.3M
Equity	$3.7M

About bioAffinity Technologies Inc

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

bioAffinity Technologies Inc is a publicly traded company under the ticker symbol BIAF on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.